|
Compound class:
Antibody
Comment: Monoclonal antibody 4A8 is a neutralising human antibody that binds to the N-terminal domain of the Spike protein of SARS-CoV-2 [1]. It was isolated from B cells collected from convalescent plasma from COVID-19 patients. 4A8 does not bind the ACE2 receptor binding domain (RBD) of the Spike protein and does not block Spike protein - ACE2 binding.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Monoclonal antibody 4A8 binds to the N-terminal domain of the Spike protein of SARS-CoV-2 with an EC50 of 5 ng/ml by ELISA [1]. It neutralises infection of Vero-E6 cells by authentic SARS-CoV-2 (EC50 of 610 ng/ml), and reduces SARS-CoV-2 virus RNA load (by qPCR) in Vero-E6 cell culture (EC50 390 ng/ml) and in ACE2-293T cells infected with a pseudotyped virus. In this same assay CR3022 showed no neutralising activity. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
